PMID- 36993723
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230529
DP  - 2023 Mar 16
TI  - The Impact of Race and Age on Response to Neoadjuvant Therapy and Long-Term 
      Outcomes in Black and White Women with Early-Stage Breast Cancer.
LID - rs.3.rs-2667554 [pii]
LID - 10.21203/rs.3.rs-2667554/v1 [doi]
AB  - PURPOSE: There are a paucity of data and a pressing need to evaluate response to 
      neoadjuvant chemotherapy (NACT) and determine long-term outcomes in young Black 
      women with early-stage breast cancer (EBC). METHODS: We analyzed data from 2,196 
      Black and White women with EBC treated at the University of Chicago over the last 
      2 decades. Patients were divided into groups based on race and age at diagnosis: 
      Black women 40 years, White women 40 years, Black women 55 years, and White women 
      55 years. Pathological complete response rate (pCR) was analyzed using logistic 
      regression. Overall survival (OS) and disease-free survival (DFS) were analyzed 
      using Cox proportional hazard and piecewise Cox models. RESULTS: Young Black 
      women had the highest risk of recurrence, which was 22% higher than young White 
      women (p=0.434) and 76% higher than older Black women (p=0.008). These age/racial 
      differences in recurrence rates were not statistically significant after 
      adjusting for subtype, stage, and grade. In terms of OS, older Black women had 
      the worst outcome. In the 397 women receiving NACT, 47.5% of young White women 
      achieved pCR, compared to 26.8% of young Black women (p=0.012). CONCLUSIONS: 
      Black women with EBC had significantly worse outcomes compared to White women in 
      our cohort study. There is an urgent need to understand the disparities in 
      outcomes between Black and White breast cancer patients, particularly in young 
      women where the disparity in outcome is the greatest.
FAU - Terman, Elizabeth
AU  - Terman E
AUID- ORCID: 0000-0002-7378-4171
AD  - Pritzker School of Medicine, The University of Chicago.
FAU - Sheade, Jori
AU  - Sheade J
AD  - Department of Medicine, Section of Hematology and Oncology, The University of 
      Chicago.
FAU - Zhao, Fangyuan
AU  - Zhao F
AD  - Department of Public Health Sciences, The University of Chicago.
FAU - Howard, Frederick M
AU  - Howard FM
AD  - Department of Medicine, Section of Hematology and Oncology, The University of 
      Chicago.
FAU - Jaskowiak, Nora
AU  - Jaskowiak N
AD  - Department of Surgery, The University of Chicago.
FAU - Tseng, Jennifer
AU  - Tseng J
AD  - Department of Surgery, City of Hope Orange County.
FAU - Chen, Nan
AU  - Chen N
AD  - Department of Medicine, Section of Hematology and Oncology, The University of 
      Chicago.
FAU - Hahn, Olwen
AU  - Hahn O
AD  - Department of Medicine, Section of Hematology and Oncology, The University of 
      Chicago.
FAU - Fleming, Gini
AU  - Fleming G
AD  - Department of Medicine, Section of Hematology and Oncology, The University of 
      Chicago.
FAU - Huo, Dezheng
AU  - Huo D
AD  - Department of Public Health Sciences, The University of Chicago.
FAU - Nanda, Rita
AU  - Nanda R
AUID- ORCID: 0000-0001-5248-0876
AD  - Department of Medicine, Section of Hematology and Oncology, The University of 
      Chicago.
LA  - eng
GR  - R25 CA240134/CA/NCI NIH HHS/United States
PT  - Preprint
DEP - 20230316
PL  - United States
TA  - Res Sq
JT  - Research square
JID - 101768035
UIN - Breast Cancer Res Treat. 2023 Apr 29;:. PMID: 37120458
PMC - PMC10055663
COIS- Competing Interests Dr. Nanda has received funding from Arvinas, AstraZeneca, 
      Celgene, Corcept Therapeutics, Genentech/Roche, Gilead/Immunomedics, Merck, OBI 
      Pharma, OncoSec, Pfizer, Relay, Seattle Genetics, Sun Pharma, Taiho. She serves 
      on the advisory board of AstraZeneca, BeyondSpring, Fujifilm, GE, Gilead, 
      Infinity, iTeos, Merck, OBI, Oncosec, Sanofi, Seagen. Dr. Fleming serves as an 
      institutional PI of an industry sponsored study for Roche, Iovance, Sermonix, 
      Campugen, Celldex, Corcept, AstraZeneca, Molecular Templates, Astellas, K group 
      beta, and Pfizer. The following companies supported a CME event organized by Dr. 
      Fleming: DSI, Merck, Caris, Eisai, AZ. The remaining authors have no relevant 
      financial or non-financial interests to disclose.
EDAT- 2023/03/31 06:00
MHDA- 2023/03/31 06:01
PMCR- 2023/03/29
CRDT- 2023/03/30 02:54
PHST- 2023/03/31 06:01 [medline]
PHST- 2023/03/30 02:54 [entrez]
PHST- 2023/03/31 06:00 [pubmed]
PHST- 2023/03/29 00:00 [pmc-release]
AID - rs.3.rs-2667554 [pii]
AID - 10.21203/rs.3.rs-2667554/v1 [doi]
PST - epublish
SO  - Res Sq [Preprint]. 2023 Mar 16:rs.3.rs-2667554. doi: 10.21203/rs.3.rs-2667554/v1.